Company Information for Provexis plc

Company stock charts - 12 Month chart

AIM; PXS View full financial data

Company Statement

Provexis discovers, develops and licenses scientifically-proven technologies for the global functional food, medical food and dietary supplement sectors.

Provexis focuses on four areas:

1. Collaborating with leading academic and research establishments to identify and co-develop proprietary technologies for the functional food, medical food and dietary supplement sectors  
2. Developing sound intellectual property protection through global patent portfolios and strong regulatory support for technologies   
3. Investing in scientific and clinical development to demonstrate efficacy and to underpin product safety   
4. Commercialising on a global basis through out-licensing technologies

Company background

Provexis Limited was founded in 1999 to commercialise a specific intellectual property and technology (Fruitflow®) which was developed at the Rowett Research Institute in Aberdeen, UK. The company remained a technology development business until 2005, at which point it merged with Nutrinnovator Holdings plc to form Provexis plc.

Nutrinnovator Holdings plc was founded in 2003 by former executives of GlaxoSmithKline's Consumer Healthcare division. The company was formed with the vision of developing and marketing innovative products for the functional food and beverage market.

The combined company combines scientific and commercial talent to ensure novel ingredients achieve their commercial potential effectively and quickly.

Current Operations

Provexis discovers, develops and licenses scientifically-proven technologies for the global functional food, medical food and dietary supplement sectors.

Fruitflow

Fruitflow is a patented, scientifically-proven tomato extract which inhibits platelet aggregation, a known cause of heart attack and stroke. Discovered by Asim Dutta-Roy at the Rowett Institute in 1999, the technology has been developed by the Provexis team in a series of clinical trials in recent years. Recent work has resulted in the filing of patents for the prevention of deep vein thrombosis. A fully commercial format has been developed for inclusion into beverage products, together with a new concentrated format ideal for incorporation into a wide range of food, dairy and dietary supplement products. See www.fruitflow.info for further information.

Provexis has a majority-owned joint venture with the University of Liverpool for the development of an extract of plantain, which is believed may increase remission time in patients with Inflammatory Bowel Disease (IBD) which includes Crohn’s Disease and ulcerative colitis. This patented technology will enter clinical trials in late 2007.
 

Board of Directors and Key Management

Stephen Moon MBA	CEO
Dawson Buck	Non-Executive Chairman
Dr Neville Bain	Non-Executive Director
Jonathan Diggines	Non-Executive Director
Ian Ford, BA (Hons) ACA	Finance Director
Dr Niamh O’Kennedy BSc MSc PhD	Director of Research & Development
Emma Wallace MEng (Hons) MIOM	Supply Chain Manager

Company Address Provexis plc Thames Court 1 Victoria Street Windsor, Berkshire, United Kingdom SL4 1YB Telephone: +44 (0)1753 752290 Facsimile: +44 (0)1753 752422 Email: enquiries[at]provexis.com Website: http://www.provexis.com

Additional Address/Key Contact Research and Development  Provexis plc Biosciences Building Crown Street Liverpool L69 7ZB United Kingdom      Provexis plc Rowett Research Institute Greenburn Road Bucksburn Aberdeen AB21 9SB United Kingdom

Capital The Company's issued share capital consists of 400,660,798 ordinary shares with a nominal value of 1p each ("Ordinary Shares"), each share having equal voting rights. The company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 400,660,798.

Annual General Meeting 24 July 2007

Year End April

Nominated Brokers Arbuthnot Securities Limited, Arbuthnot House, Ropemaker Street London, EC2Y 9AR

Nominated Advisors Arbuthnot Securities Limited, Arbuthnot House, Ropemaker Street London, EC2Y 9AR

Major Shareholders

At 16 August 2007 the following interests of shareholders in excess of 3% have been notified to the company:
Name	Number of Ordinary Shares held	% of issued share capital
Rising Stars Growth Fund	76,459,444	19.08
ANGLE Technology Limited	47,426,464	11.84
Progeny Bioventures Limited	31,969,179	7.98
Cantor Fitzgerald Europe	26,991,666	6.74
City Equities Ltd	20,093,334	5.02
North West Equity Fund	13,514,990	3.37

Most Recent Statement

09/08/07 - Additional Listing
02/08/07 - Change of Registered Office
24/07/07 - Notification of Major Interest in Shares
23/07/07 - AGM Statement
10/07/07 - Directorate Change
02/07/07 - Annual Report and Accounts